|
AU2013273775A1
|
|
Antibody single variable domains against serum albumin
|
|
US2013216538A1
|
|
Compositions and Methods for Treating Inflammatory Disorders
|
|
WO2010081787A1
|
|
IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
|
|
MX2011004245A
|
|
Composition for targeting dendritic cells.
|
|
CN102257009A
|
|
Ligands that have binding specificity for dc-sign
|
|
EP2315778A2
|
|
Compositions monovalent for cd28 binding and methods of use
|
|
US2011097339A1
|
|
Compositions monovalent for CD28 binding and methods of use
|
|
EP2279208A1
|
|
Single domain antibodies that bind il-13
|
|
WO2009138413A1
|
|
Single domain antibodies that bind il-13
|
|
AU2008364461A1
|
|
Ligands that bind IL-13
|
|
MX2009013137A
|
|
Methods for selecting protease resistant polypeptides.
|
|
WO2008149147A2
|
|
Polypeptides, antibody variable domains and antagonists
|
|
AU2008201371A1
|
|
A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
|
|
KR20090114445A
|
|
Antibody single variable domains against serum albumin
|
|
US2008241166A1
|
|
Ligands that bind a receptor
|
|
GB0724331D0
|
|
Compositions for pulmonary delivery
|
|
MY144715A
|
|
Compositions monovalent for cd40l binding and methods of use
|
|
KR20080098382A
|
|
Ligands that bind il-4 and/or il-13
|
|
CA2640066A1
|
|
Fusion proteins that contain natural junctions
|
|
CA2633742A1
|
|
Composition
|
